CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein

British Journal of Cancer

Volumn 77, Issue 3, 1998, Pages 359-365

  Jansen, W J M ^a   Hulscher, T M ^a   Van Ark Otte, J ^a   Giaccone, G ^a   Pinedo, H M ^a   Boven, E ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

CPT 11; Multidrug resistance associated protein; P170 glycoprotein; Topoisomerase

Indexed keywords

CAMPTOTHECIN DERIVATIVE; CARBOXYLESTERASE; DEXNIGULDIPINE; DNA TOPOISOMERASE; DOXORUBICIN; GLYCOPROTEIN; IRINOTECAN; MULTIDRUG RESISTANCE PROTEIN; VERAPAMIL; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CROSS RESISTANCE; DNA DENATURATION; FEMALE; HUMAN; HUMAN CELL; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

EID: 0031962772     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.58     Document Type: Article

References (33)

1. Abigerges D, Chabot GG, Armand JP, Hérait P, Gouyette A and Gandia D (1995) Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13: 210-221
2. Chang JY, Dethlefsen LA, Barley LR, Zhou B and Cheng YC (1992) Characterization of camptothecin-resistant Chinese hamster lung cells. Biochem Pharmacol 43: 2443-2452
3. Chen AY, Yu C, Potmesil M, Wall ME, Wani MC and Liu LF (1991) Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res 51: 6039-6044
4. Cole SPC, Chanda ER, Dicke FP, Gerlach JH and Mirski SEL (1991) Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II. Cancer Res 51: 3345-3352
5. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV and Deeley RG (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650-1654
6. Giaccone G, Van Ark-Otte J, Scagliotti G, Capranico G, Van der Valk P, Rubio G, Dalesio O, Lopez R, Zunino F, Walboomers J and Pinedo HM (1995) Differential expression of DNA topoisomerases in non-small lung cancer and normal lung. Biochem Biophys Acta 1264: 337-346
7. Goldwasser F, Bae I, Valenti M, Torres K and Pommier Y (1995) Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. Cancer Res 55: 2116-2121
8. Gupta M, Fujimori A and Pommier Y (1995) Eukaryotic DNA topoisomerases I. Biochem Biophys Acta 1262: 1-14
9. Hasegawa S, Abe T, Naito S, Kotoh S, Kumazawa J, Hipfner DR, Deeley RG, Cole SPC and Kuwano M (1995) Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines. Br J Cancer 71: 907-913
10. Hendricks CB, Rowinsky EK, Grochow LB, Donehower RC and Kaufmann SH (1992) Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res 52: 2268-2278
11. Houghton PJ, Cheshire PJ, Hallman JC, Bissery MC, Mathieu-Boué A and Houghton JA (1993) Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. Cancer Res 54: 2823-2829
12. Jansen WJM, Pinedo HM, Kuiper CM, Lincke C, Bamberger U, Heckel A and Boven E (1994) Biochemical modulation of 'classical' multidrug resistance by BIBW22BS, a potent derivative of dipyridamole. Ann Oncol 5: 733-739
13. Jansen WJM, Zwart B, Hulscher TM, Giaccone G, Pinedo HM and Boven E (1997a) CPT-11 in human colon cancer cell lines and xenografts: characterization of cellular sensitivity determinants. Int J Cancer 70: 335-340
14. Jansen WJM, Kolfshoten GM, Erkelens CAM, Van Ark-Otte J, Pinedo HM and Boven E (1997b) Antitumor activity of CPT-11 in experimental human ovarian cancer and human soft tissue sarcoma. Int J Cancer (in press)
15. Juan CC, Hwang J, Liu AA, Whang-Peng J, Knutsen T, Huebner K, Croce CM, Zhang H, Wang JC and Liu LF (1988) Human DNA topoisomerase I is encoded by a single-copy gene that maps to chromosome region 20q12-13.2. Proc Natl Acad Sci USA 85: 8910-8913
16. Kaneda N and Yokokura T (1990) Nonlinear pharmcokinetics of CPT-11 in rats. Cancer Res 50: 1721-1725
17. Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M, Yokokura T, Sawada S, Miyasaka T and Mutai M (1987) Antitumor activity of 7-ethyl-10-[14-(1-pineridino)-1-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 47: 5944-5947
18. Lincke CR, Van Der Bliek AM, Schuurhuis GJ, Van Der Velde-Koerts T, Smit JJM and Borst P (1990) Multidrug resistance phenotype of human BRO melanoma cells transfected with a wild-type human mdr1 complementary DNA. Cancer Res 50: 1779-1785
19. Ling V (1992) P-glycoprotein and resistance to anticancer drugs. Cancer 69: 2603-2509
20. Liu LF and Miller KG (1981) Eukariotic DNA topoisomerases: two forms of type I DNA topoisomerases from HeLa cell nuclei. Proc Natl Acad Sci USA 78: 3487-3491
21. Lokiec F, Monegier du Sorbier B and Sanderink GJ (1996) Irinotecan (CPT-11) metabolites in human bile and urine. Clin Cancer Res 2: 1943-1949
22. Mattern MR, Hofmann GA, Polsky RM, Funk LR, McCabe FL and Johnson RK (1993) In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells. Oncol Res 5: 467-474
23. Niwa K, Misao R, Hanabayashi T, Morishita S, Murase T, Itoh M, Itoh N, Mori H and Tamaya T (1994) Semi-quantitative analysis of DNA topoisomerase-I mRNA level using reverse transcription-polymerase chain reaction in cancer cell lines: its relation to cytotoxicity against camptothecin derivative. Jpn J Cancer Res 85: 869-874
24. Rogan AM, Hamilton TC, Young RC, Klecker RW and Ozols RF (1984) Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science 224: 994-996
25. Slichenmyer WJ, Rowinsky EK, Donehower RC and Kaufmann SH (1993) The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 85: 271-291
26. Tsuji K, Kaneda N, Kado K, Yokokura T, Yoshimoto T and Tsuru D (1991) CPT-11 converting enzyme from rat serum: purification and some properties. J Pharmacobio Dyn 14: 341-349
27. Tsuruo T, Matsuzaki T, Matsushita M, Saito H and Yokokura T (1988) Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother Pharmacol 21: 71-74
28. Versantvoort CHM, Broxterman HJ, Feller N, Dekker H, Kuiper CM and Lankelma J (1992) Probing daunorubicin accumulation defects in non-P-glycoprotein expressing multidrug-resistant cell lines using digitonin. Int J Cancer 50: 906-911
29. Wall ME, Wani MC, Cook CE, Palmar KH, McPhail AT and Sim GA (1966) Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloid leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 88: 3888-3890
30. Woessner RD, Eng WK, Hofmann GA, Rieman DJ, McCabe FL, Hertzberg RP, Mattern MR, Tan KB and Johnson RK (1992) Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content. Oncol Res 4: 481-488
31. Zaman GJR, Versantvoort CHM, Smit JJM, Eijdems EWHM, De Haas M, Smith AJ, Broxterman HJ, Mulder NH, De Vries EGE, Baas F and Borst P (1993) Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res 53: 1747-1750
32. Zaman GJR, Flens MJ, Van Leusden MR, De Haas M, Mülder HS, Lankelma J, Pinedo HM, Scheper RJ, Baas F, Broxterman HJ and Borst P (1994) The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci USA 91: 8822-8826
33. Zamora JM, Pearce HL and Beck WT (1988) Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol Pharmacol 33: 454-462